Advertisement
Canada markets closed

  • S&P/TSX

    21,875.79
    -66.37 (-0.30%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.20 (-0.12%)
     

  • CAD/USD

    0.7312
    +0.0011 (+0.15%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • Bitcoin CAD

    82,583.91
    -1,709.82 (-2.03%)
     

  • CMC Crypto 200

    1,257.76
    -26.07 (-2.03%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • RUSSELL 2000

    2,047.69
    +9.35 (+0.46%)
     

  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     

  • NASDAQ

    17,732.60
    -126.08 (-0.71%)
     

  • VOLATILITY

    12.44
    +0.20 (+1.63%)
     

  • FTSE

    8,164.12
    -15.56 (-0.19%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • CAD/EUR

    0.6820
    +0.0003 (+0.04%)
     

Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock

Zacks Equity Research
·2 min read

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.

Why This 1 Growth Stock Should Be On Your Watchlist

Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

ADVERTISEMENT

Vertex Pharmaceuticals (VRTX)

Boston, MA-based Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company’s main area of focus is cystic fibrosis (CF).

VRTX boasts a Growth Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 12.5% year-over-year for 2024, while Wall Street anticipates its top line to improve by 8.6%.

Seven analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.25 to $17.13 per share. VRTX boasts an average earnings surprise of 5.9%.

Vertex Pharmaceuticals is also cash rich. The company has generated cash flow growth of 36.2%, and is expected to report cash flow expansion of 5.2% in 2024.

Investors should take the time to consider VRTX for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research